CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department More than 27,569 individuals…
USA News Group Commentary Issued on behalf of BioVaxys Technology Corp. VANCOUVER, BC, Aug. 19, 2024 /PRNewswire/ -- USA News…
Project aims to increase access of advanced imaging techniques for clinicians to help drive improved diagnosis and management of female…
REDDING, Calif., Aug. 19, 2024 /PRNewswire/ -- According to a new market research report titled, "Real-world Evidence Solutions Market Size, Share, Forecast,…
The panel of experts will present the Zoom webinar to Tennessee Brokers as a Guide to Cost-Effective Health Coverage Options…
Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision medicine by…
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…
FORT LAUDERDALE, FL / ACCESSWIRE / August 19, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…
MIAMI, FL / ACCESSWIRE / August 19, 2024 / MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) "MIRA" or the "Company"), a leading pre-clinical-stage…
Three months post cessation of an 8-week course of microdosing treatment, the antidepressant response is sustained with a 62.8% reduction…